Recombinant Adeno-Associated Virus Expressing human Antisense Gene Cyp2j2 and Its Preparation Methods

ABSTRACT

A recombinant adeno-associated virus expressing antisense human CYP2J2 gene and preparation method thereof are provided, the recombinant adeno-associated virus is prepared through cloning human CYP2J2 cDNA (1509 bp, which encode the protein containing 503 amino acids) from human leucocyte DNA by PCR, cotransfecting three plasmids by the calcium phosphate precipitation technique to pack and prepare the recombinant adeno-associated virus containing the antisense target gene, and purifying. The recombinant adeno-associated virus obtained from the above method can be transfected into different kinds of human tumor cell lines, inhibiting the proliferation and migration of tumor cells, promoting the apoptosis of tumor cells and suppressing the growth and metastases of tumor. Therefore, it can prove that the selective inhibitor of CYP2J2 and the recombinant adeno-associated virus expressing antisense human CYP2J2 gene are the potential medicine for treating tumor.

FIELD OF THE INVENTION

The invention relates to the construction and preparation method of recombinant adeno-associated virus expressing antisense human CYP2J2 gene (rAAV-anti2J2, and more specifically to cloning of human CYP2J2 gene, a package and preparation method of recombinant adeno-associated virus containing the antisense CYP2J2 gene and pharmacy applications of recombinant adeno-associated virus and tumor treatment with CYP epoxygenase selective inhibitor and epoxyeicosatrienoic acids blocker.

BACKGROUND OF INVENTION

With extensive study and understanding of cytochrome P450 (CYP) epoxygenase, much attention has been increasingly devoted to its function in physiology and pathophysiology. Especially, the CYP metabolic pathway of arachidonic acid discovered 20 years ago has been suggested to be focal points in the present research of human biology and pathophysiology. AA-CYP epoxygenase metabolizes arachidonic acid to four different epoxyeicosatrienoic acids (EETs), namely 5, 6-, 8, 9-, 11, 12-, 14, 15-EETs. CYP epoxygenase consists of two types, 2C and 2J. Some studies have indicated that 2C is widely distributed in organism, particularly abounds in liver and is also expressed in vein. At present six clones of 2J have been found and there is only 2J2 expressed in human, most abundantly in heart and vascular endothelial cells. It has been found by us and foreign experts that EETs play an important role in the homeostasis regulation of cardiovascular system, including regulation of blood pressure and protection of heart and antiapoptosis of vascular endothelial cells. However, our research indicates that epoxygenase gene selectively overexpresses in human tumor tissues, promoting the proliferation and metastases of tumor cells and decreasing the apoptosis of tumor cells, which shows extremely positive significance in tumor treatment. Tumor is a frequent and common disease of people in modern society, with bad prognosis and high mortality, and has been a main cause of death in our country and even in the world. It is a multigenic, multistep and multistage regulated chronic disease and its treatment by commonly used drugs cannot be attended with good results at present. But with the development of the theory and technology of molecular biology and the advent of gene therapy, it is possible to get good results of tumor treatment. As an important medical industry in the 21st century, there are still many disadvantages to overcome in gene therapy, especially the choice of gene therapy vectors.

To make the gene therapy for tumor come true really, we construct the recombinant adeno-associated virus recombined with antisense human CYP2J2 cDNA and obtain detected high titer virus meeting the requirements of treatment. It has been verified in animal experiments that it can inhibit the growth of tumor cells So there is a hope of truly meeting the requirements of clinic treatment. In addition, we study the function and mechanism of AA-CYP epoxygenase inhibitor inhibiting the proliferation of malignant tumor and demonstrate the pharmacy applications of AA-CYP epoxygenase selectively overexpressing in human tumor and its inhibitor inhibiting the proliferation of malignant tumor.

SUMMARY OF THE INVENTION

The author of the invention inserts the CYP2J2 cDNA inversely into the eukaryotic expression vector pXXUF₁ to construct a recombinant plasmid pXXUF₁-anti2J2 successfully. Then by the calcium phosphate precipitation technique, pXX₂, pXX₆ and pXXUF₁-anti2J2 are cotransfected into 293 cell to pack and prepare the recombinant adeno-associated virus expressing antisense human CYP2J2 (rAAV-anti2J2), which is purified by heparin column and its titre is measured by dot blot hybridization. Moreover, the packed and prepared recombinant adeno-associated virus is transfected into different kinds of human tumor cell lines and it has been verified by experiments that the recombinant adeno-associated virus containing the antisense CYP2J2 can obviously inhibit the proliferation and migration of tumor cells and promote the apoptosis, and rAAV-anti2J2 can inhibit obviously the growth of tumor cells through transporting the cell lines transfected with rAAV-anti2J2 to the subcutaneous tissues of nude mice. In addition, CYP2J2 selective inhibitor also shows the same function. So it provides a whole new idea and direction for developing new medicines for treating tumor.

As described above, the first purpose of the invention is to provide the recombinant adeno-associated virus containing the antisense human CYP2J2 gene.

The second purpose of the invention is to provide the package and preparation process of the recombinant adeno-associated virus containing the antisense human CYP2J2 gene.

The third purpose of the invention is to provide the experimental methods and results of inhibiting the proliferation of tumor cells and treating tumor by using CYP epoxygenase selective inhibitor and EET blocker.

The fourth purpose of the invention is to provide the experimental methods and results of treating tumor by using the recombinant adeno-associated virus containing the antisense human CYP2J2 gene.

To achieve the purposes of the invention, the inventor designs a recombinant adeno-associated virus expressing antisense human CYP2J2 gene and its preparation method. The recombinant adeno-associated virus provided in the invention is prepared through cloning human CYP2J2 cDNA (1509 bp, which encodes the protein containing 503 amino acids) from human leucocyte DNA by PCR, cotransfecting three plasmids by the calcium phosphate precipitation technique to pack and prepare the recombinant adeno-associated virus containing the antisense target gene, and purifying. The recombinant adeno-associated virus prepared from the above method can be transfected into different kinds of human tumor cell lines, obviously inhibiting the proliferation and migration of tumor cells, promoting the apoptosis of tumor cells and suppressing the growth and metastases of tumor. Therefore, it is proved that the selective inhibitor of CYP2J2 and the recombinant adeno-associated virus expressing human antisense gene CYP2J2 are the potential medicine for treating tumor.

Three plasmids contained in the recombinant adeno-associated virus in the invention: pXX₂: a packing plasmid carrying sequences encoding adeno-associated virus Rep and Cap protein. A p5 promoter is inserted in upstream and downstream respectively making the expression efficiency increase 15-fold and providing the essential Rep proteins for rAAV duplication;

pXXUF₁: a eukaryotic expression plasmid vector containing a CMV promoter and having a strong expression efficiency in which the NotI site in multiple cloning sites can link different target genes. pXXUF₁ links the CYP epoxygenase gene inversely and contains inverted terminal repeats (ITRs) that are essential for the expression of rAAV-mediated transgenosis and responsible for the replication of virus, package of virus capsid and carrying target genes;

pXX₆: a helper plasmid deleting the pathogenic gene sequences of adenovirus and preserving the E1A, E2A and VA1 RNA genes of adenovirus. The expressed proteins can help to stimulate the transcription and translation of rAAV gene, so the yield of rAAV can be ensured; and

Cotransfect three plasmids above into 293 cell by the calcium phosphate precipitation technique and obtain high titre rAAV particles containing target genes in 293 cell.

The procedure of preparation of recombinant adeno-associated virus in the invention is as follows:

Plasmid pXX₂- - - carrying sequences encoding Rep and Cap protein that are essential for package of adeno-associated virus, and plasmid pXX₆- - - carrying E1A, E2A and VA1 RNA genes of adenovirus that are essential for stimulating the replication and transcription of adeno-associated virus;

A eukaryotic expression vector pXXUF₁ containing the adeno-associated virus genome, in which the coding regions of Cap and Rep protein are deleted and the antisense human CYP2J2 gene is inserted to constitute a recombinant plasmid pXXUF₁-anti2J2;

pXX₂, pXX₆ of step (1) and pXXUF₁-anti2J2 of step (2) are cotransfected into 293 cell by the calcium phosphate precipitation technique, which is then recovered and purified, and the virus titre is measured by dot blot hybridization; and

Detect the expression and biological activity of virus in tumor cells transfected with the recovered and purified virus of step (3).

The invention is further described in detail.

To acquire human CYP2J2 gene, the inventor designs specific primers to amplify CYP2J2 cDNA fragment from CYP2J2 nucleotide sequences reported in the GenBank. Genomic DNA is isolated from human leucocyte by phenol-chloroform extraction and used as a template for PCR (Takara PCR kit, Japan; PCR device, Techne, UK). The product is joined inversely to pXXUF₁ to construct a recombinant vector pXXUF₁-anti2J2, which is introduced host cells, namely E. coli, and positive clones can be obtained.

The package of recombinant adeno-associated virus requires three plasmids as following:(1)pXX₂: a packing plasmid carrying sequences encoding adeno-associated virus Rep and Cap protein. A p5 promoter is inserted in upstream and downstream separately to make the expression efficiency increase 15-fold; (2)pXX₆: a helper plasmid deleting the pathogenic gene sequences of adenovirus and preserving E1A, E2A and VA1 RNA genes of adenovirus. The expressed proteins can help to stimulate the transcription and translation of rAAV gene, so the yield of rAAV can be ensured; (3) pXXUF₁-anti2J2: a eukaryotic expression vector with human CYP2J2 joined inversely, which contains a CMV promoter with strong expression efficiency and inverted terminal repeats (ITRs) that are essential for the expression of rAAV-mediated transgenosis and responsible for replication of virus, package of virus capsid and carrying target genes. Calcium phosphate cotransfect the mixture of pXX₂, pXX₆ and pXXUF₁-anti2J2 (molar ratio is 1:1:1) into 293 cell and after 48-72 h harvest 293 cell. After three freeze and thaw cycles of 293 cell, virus is delivered into the supernatant and then purified by heparin column, and its titre is measured by dot blot hybridization. So the recombinant adeno-associated virus containing the antisense human 2J2 gene is obtained.

Then to verify the function of CYP epoxygenase in the generation and development of tumor and the therapeutic action of CYP epoxygenase selective inhibitor and recombinant adeno-associated virus containing the antisense 2J2 gene against the tumor, we study and explore the selective high expression of CYP epoxygenase in human tumor tissues and prove that the rAAV-anti2J2 can obviously decrease the expression of 2J2 in tumor cells. Transfection of antisense CYP epoxygenase gene (rAAV-anti2J2), together with utilization of the CYP epoxygenase inhibitor(17-ODYA), can obviously suppress the proliferation of tumor cells, which is below 50% of basal state(P<0.01). But transfection of rAAV-CYP2J2 can obviously promote the proliferation of tumor cells and the number of proliferating cells is 2-3fold higher than basal state, namely rAAV-GFP-transfected and nontranfected cells. Equally transfect rAAV-anti2J2 into human tongue squamous cell carcinoma cell line Tca-8113, then transplant it to the subcutaneous tissues of nude mice to partially simulate the process of growth of tumor cells, measure the size of tumor and shape the growth curve of tumor volume. So it proves that transfection of rAAV-anti2J2 can obviously inhibit the growth of tumor.

In addition, it is found through measuring the microvessel density of tumor tissues that transfection of rAAV-anti2J2 can decrease obviously the microvessel density in tumor

Similarly, transfection of rAAV-anti2J2 can obviously inhibit the migration of tumor cells and promote the apoptosis of tumor cells.

The results mentioned above show rAAV-anti2J2 and CYP epoxygenase inhibitor (17-ODYA) can inhibit the proliferation and migration of tumor and promote the apoptosis of tumor cells, so they can be used for tumor treatment. With successful construction of recombinant adeno-associated virus expressing antisense human CYP2J2 gene (rAAV-anti2J2), its long-term high expression in organism blocks the transcription and translation of CYP2J2 gene in gene level, decreases the expression of CYP2J2, and shows stronger and more thorough function. The clinical utilization of recombinant adeno-associated virus expressing antisense human CYP2J2 gene (rAAV-anti2J2) and epoxygenase inhibitor will play an important role in the treatment for the disease which is harmful to human health as tumor etc.

The superiority of the invention lies in the fact that the studied and explored recombinant adeno-associated virus vector has overcome the disadvantages that other gene expression vectors cannot overcome and the carried target gene can be transfected into cells in division stage and non-division stage(with wide range of transgenosis) with no immunogenicities and high infection efficiency and drive long-term expression of target genes in vivo, successfully solving the problem of high replication in vitro with no adenovirus polluting.

BRIEF DESCRIPTION OF THE DRAWINGS

The further mentioned above and other purposes and characteristics of the invention are explained more clearly by following drawings.

FIG. 1 A/B shows 2J2 sequences (from GeneBank) with the region of cDNA open reading frame light-colored;

FIG. 2 shows the composition of plasmid pXXUF₁-anti2J2;

FIG. 3 shows the nucleotide sequences and detailed regions of adeno-associated virus;

FIG. 4 shows the structure diagram of adeno-associated virus genome;

FIG. 5 shows ITR sequences of adeno-associated virus and their secondary structure diagram;

FIG. 6 shows the transcription and translation of adeno-associated virus (part 1);

FIG. 7 shows the transcription and translation of adeno-associated virus (part 2);

FIG. 8 shows structural map of plasmid pXX₂ and pXX6;

FIG. 9 shows the composition of plasmid pXXUF₁ (the map only shows the main regions of plasmid. Actually the two plasmids have already been converted to 5000-7000 bp cyclic structure, but other parts are unshown for insignificance);

FIG. 10 A/B shows the effective expression of transfected CYP epoxygenase gene (rAAV-2J2) and that transfected antisense gene (rAAV-anti2J2) can obviously inhibit the expression of CYP2J2 in tumor cells. In FIG. 10A, the effective expression of transfected CYP epoxygenase gene (rAAV-2J2) and the transfected antisense gene (rAAV-anti2J2) can obviously inhibit the expression of CYP2J2 in tumor cells. A: Result of CYP-2J2 Western Blot of proteins extracted from transplantation tumor tissues 32 days after the proceed by which rAAV-2J2 and rAAV-anti2J2 are transfected respectively into tumor cells, which are then transplanted to the subcutaneous tissues of nude mice to form transplantation tumor. B: Result of CYP-2J2 Western Blot of proteins extracted directly from tumor cells that rAAV-2J2 and rAAV-anti2J2 are respectively transfected into. Both the two results show that transfected rAAV-2J2 can express effectively in tumor cells, but transfected rAAV-anti2J2 can obviously inhibit or block the expression of CYP2J2, which are closely related to the fact that CYP2J2 can result in malignant proliferation of tumor and rAAV-anti2J2 can inhibit malignant proliferation of tumor;

FIG. 11 shows the CYP epoxygenase has an effect on proliferation of four tumor cell lines;

FIG. 12 shows the growth curve of transgenic tumor;

FIG. 13 shows the result of microvessel density in transgenic tumor tissues;

FIG. 14 A/B shows the CYP epoxygenase has an effect on invasive ability of tumor cells;

FIG. 15 shows the CYP epoxygenase inhibitor (17-ODYA) dose-dependently inhibits the growth of tumor cells;

FIG. 16 shows the EET repressor 14, 15-EET (100 nmol/L) can inhibit the growth of tumor; and

FIG. 17 shows the epoxygenase inhibitor 17-ODYA can inhibit the growth of transplantation tumor without joint use of 5-fluorouracil.

DETAILED DESCRIPTION OF THE INVENTION EMBODIMENT 1 Cloning of CYP2J2 cDNA and Preparation of a Recombinant Plasmid pXXUF₁-anti2J2

To clone human CYP2J2 cDNA, design PCR primers amplifying CYP2J2 cDNA according to public CYP2J2 gene sequences (FIG. 1), which are upstream primer 5′-GCCCGGAATTCAAAATGATTCTCAAC-3′ and downstream primer 5′ -GG CGCACAAGCTTTCAAATAAGAGTATAAC-3′ synthesized by Wuhan Biosynthesis Company. Genomic DNA is isolated from human leucocyte by phenol-chloroform extraction and used as a template for PCR (Takara PCR kit, Japan; PCR device, Techne, UK).The product is joined inversely to pXXUF₁ to construct a recombinant vector pXXUF₁-anti2J2 as shown in FIG. 2.

EMBODIMENT2 Package, Recovery and Purification of the Recombinant Virus rAAV-anti2J2

-   -   I. Features of natural adeno-associated virus (AAV) and         recombinant adeno-associated virus (rAAV):

Adeno-associated virus is an animal single strand DNA virus, belonging to family Parvoviridae, subfamily Parvovirinae, genus Dependovirus, and is naturally defective, non-enveloped and non-pathogenic.

1. AAV has a Linear Single-stranded DNA Genome of 4680 Nucleotides (sequences as shown in FIG. 3), characterized in that:

-   -   1) The genome is composed by 4 open reading frames (ORF): rep,         lip, inf and cap(FIG. 3, FIG. 4). On the left side of the genome         DNA, there is a big ORF which can inhibit DNA from replicating         by frame shift mutation or deletion. So it is called rep. The         big ORF called cap on the right side encodes three capsid         proteins. Other two small ORFs locate in the middle of genome         DNA called inf and lip, whose function is not explicit;     -   2) There are inverted terminal repeat (ITR) sequences at both         ends of the DNA strands. The ITRs form a hairpin structure as an         only known cis-acting element required for initial replication         of DNA and packing rAAV genome to form infective virus particles         as shown in FIG. 5;     -   3) The replication and transcriptional regulation of         adeno-associated virus are quite sophisticated and divided into         two kinds of expression patterns that are proliferative and         latent according to whether there exists cotransfection of         helper virus or not (as shown in FIG. 6).

During the proliferative expression of AAV, 6 kinds of MRNA are transcribed from P5, P19 and P40 promoter respectively as shown in FIG. 7. During the cotransfection of adenovirus (Ad), the E1A gene of Ad is responsible for trans-activating expression of AAV genes, and the E2A gene of Ad encodes a single strand DNA binding protein, which stimulates the AAV promoter to promote transcription and after transcription helps transport AAV from intranucleus to cytoplasm. In addition, the VA1 RNA of Ad can probably be favorable to the initiation of translation of AAV proteins and AAV can regulate the expression of self genes and helper virus genes positively and negatively. Rep gene products of AAV can positively and negatively regulate P5, P19 and P40 promoter to initiate transcription. While Ad exists, the products of rep gene perform positive regulation, and without cotransfection of helper virus, the products of rep gene do negative regulation.

Without helper virus, DNA of AAV can be integrated into the host cell genome in the form of double strand and persist in latent form for latent infection of AAV. The specific site of integration of AAV locates in the 19q13.3-19q ter of human chromosome. Besides negative regulation of rep gene products, they also recognize and bind the specific site of integration that is GGTG sequence, and mediate the recombinantion(recombination) between ITR and integrating site. The infection of adenovirus can promote AAV to be proliferative and infected.

2. AAV is used as a Vector for Gene Therapy

As far as we know, AAV is a unique eukaryote cells virus integrating into the specific site of chromosome of host genome, which offers a new hope for gene therapy. Compared with nonintegrated vector as vectors based on adenovirus, the AAV vector not only expresses the transgenosis more constantly and stably, but also decreases the insertional mutation rate theoretically resulting from random integration of transgenosis. The vector system we used is obtained through a series of splice and modification of natural recombinant adeno-associated virus and adenovirus by molecular biology methods, preserving essential parts for replication and transcription of recombinant adeno-associated virus and auxiliary parts of adenovirus late genes and deleting all other unnecessary parts, thus makes latent infection of virus long and stable and avoids pathogenic danger from adenovirus. Moreover, the expression of late genes of adenovirus can ensure the expression efficiency of cloned gene. The vector system comprises as following:

pXX₂ (FIG. 8): Preserve cap and rep genes of AAV (pAGG-2 is obtained now) and insert a p5 promoter into the suitable position in the downstream of pACG-2(the original position is cute off with XbaI and PstI and joined to the suitable position in pACG-2);

pXX₆ (FIG. 8): pXX₆ is obtained through cloning a fragment cute with ClaI and SalI from pXX₅ into pBS, only leaving coding regions of E2A, E4 and VA, wherein pXX₅ is obtained through cutting a 8 kb fragment with PmeI and SgfI from the adenovirus rebult plasmid pBH10(E1, E3 gene and packaging signal have been deleted);

pXXUF₁ (FIG. 9): Plasmid pXXUF₁ required for package of rAAV contains gfp gene driven by the CMV promoter(arrow),wherein gfp gene is introduced into the NotI site after deleting all the encoding genes of recombinant adeno-associated virus, and is converted to circularity which is easy for gene cloning and expression.

II, Package and Recovery of Recombinant Virus rAAV-anti2J2

Large-scale extraction of plasmid pXX₂ , pXX₆ and pXXUF₁-anti2J2 are purified by using DNA Purification Systems (Promega). The specific preparation method is following the instructions.

Transfer the 293 cell (human neuroblastoma cell lines) into several 150 mm culture plates for subcultivation requiring 0.25% trypsin, high sugar DMEM media and neonatal bovine serum (Gibco). When cells grow to 60%-70% of crowding level, calcium phosphate cotransfect the mixture of plasmid pXX₂, pXX₆ and pXXUF₁-anti2J2 (molar ratio 1:1:1, mass ratio 1.7:3.8:1) into 293 cell based on total quantity 85 μg DNA per 150 mm culture plate. At first, add plasmid pXX₂, pXX₆ and pXXUF₁-anti2J2 respectively to a 250 mL sterile culture flask. Then add in turn 2.5M CaCl₂ (160 μL per plate) and sterile deionized water. At last, add 2×BBS (pH6.95, 1.6 mL per plate) drop by drop and shake the mixture to form small calcium phosphate particles. Incubate at room temperature for 30 min. Discard the media in 293 cell culture plates by aspiration, then add 3 mL DNA-calcium phosphate complexes, and incubate at 35° C. with 3% CO₂ for 16-24 h. Change culture media and continue to culture at 37° C. with 3% CO₂ for 36-48 h. Discard all the media by aspiration 48-72 h after transfection, add little PBS buffer, scrape the 293 cell in plates, and store at −80° C.

To remove allotype proteins in cells, purification by heparin column is required as following. After three repeat freeze and thaw cycles of harvested 293 cell containing the virus, add 0.1 mg DNase I and 0.1 mg RNase A and incubate at 37° C. for 2 h. Then add 0.5% deoxycholic acid and incubate at 37° C. for 30 min. Spin for several minutes and filter the supernatant through 5 μm and 0.8 μm filter membranes. Transfer 8 mL of heparin agarose suspensions into a 2.5 cm diametral glasscolumn with a valve. After agarose suspensions drain away, place a filter membrane on the formed agarose bed and pump 25 mL of PBS (pH7.4) through the bed. Shut the valve, add the filtered virus above to the glasscolumn, open the valve and adjust the flow rate of virus to 1 drop per second. After the virus drips off, wash the column twice with 25 mL of PBS (pH7.4) and 0.1M NaCl. Wash the virus with 15 mL of PBS (pH7.4) and 0.4M NaCl and concentrate the virus solution to 3-5 mL with a Millipore Biomax-100K NMWL filter device (UFV2BHK40).

EMBODIMENT 3 Measurement of rAAV-anti2J2 Virus Titre by Dot Blot Hybridization

(1) Labeling and Purification of CYP2J2 cDNA Probe

Isotope-labeled nucleotide α-p³² is purchased from Beijing Yahui Co. Ltd. CYP2J2 fragment is cut off from pXXUF₁-anti2J2 with Not I and used as a probe of known sequence. Label CYP2J2 fragment by random priming and purify. The kits are purchased from Qiagen Co. and specific method is following the instructions.

(2) Preparation of Recovered Materials and Quantitative Criteria

The recovered materials are prepared through the proceed by which digest the DNA and RNA of cell genome with the right amount of DNase I and RNase A, then add proteinase K to digest the virus capsid (all reagents above are from Takara Co.), extract with phenol: chloroform: isoamyl alcohol (25:24:1) to remove pellet and obtain virus DNA in supernatants. As a standard substance, the target gene fragment, namely CYP2J2 fragment, is double diluted after measuring its concentration and treated through heating and alkali denaturation.

(3) Hybridization and Radioautography

Furnish the device of dot blot hybridization and set a 0.45 μm nylon membrane according to the size of device. Load the measuring virus samples and standard samples along volume gradient and molecular gradient respectively, then bake the membrane at 80° C. for 2 h and prehybridize at 42° C. for 1 h(prehybridization solution is from INTERGRN Co.).Add labeled probe that is heat treated in advance and hybridized at 45° C. for 12-16h. Wash the membrane and radioautograph at −80° C. for 2-3 days. The prepared rAAV titre reaches 1×10¹¹p.f.u. and can be used for animal experiments.

EMBODIMENT 4 Influence of CYP Epoxygenase on the Growth and Erosion of Tumor

(1) Effective Expression in Tumor Cell Lines of CYP Epoxygenase Gene Transfected into Subcutaneous Transplantation Tumor

Extract proteins in tissues from subcutaneous transplantation tumor of nude mice and tumor cell lines of control group and transfected rAAV-GFP, rAAV-anti2J2, rAAV-CYP2J2 group. Detect the effective expression of epoxygenase in tissues by western blot. The result shows the expression in the transfected rAAV-anti2J2 group decreases obviously compared with control group and there is no marked difference between the transfected rAAV-GFP group and control group as shown in FIG. A and B.

(2) Influence of CYP Epoxygenase and its Inhibitor on Proliferation of Four Tumor Cells in vitro

Transfect rAAV-CYP2J2 and rAAV-CYPF87V into tumor cells to make them overexpress the epoxygenase, which can metabolize arachidonic acid to endogenous epoxyeicosatrienoic acids and indirectly increase their concentration, thus it is verified directly that CYP epoxygenase can promote proliferation. Compared with the control group, transfected rAAV-CYP2J2 and rAAV-CYPF87V can obviously promote the proliferation of tumor cells and the number of proliferating cells is 2-3fold higher than basal state, namely rAAV-GFP-transfected and nontranfected cells(P<0.01). Transfection of antisense CYP epoxygenase gene (rAAV-anti2J2), together with utilization of the CYP epoxygenase inhibitor (17-ODYA), can suppress obviously the proliferation of tumor cells which is below 50% of basal state(P<0.01) as shown in FIG. 11.

(3) Influence of rAAV-antiCYP Epoxygenase on the Growth of Transplantation Tumor of Nude Mice with Human Tongue Squamous Cell Carcinoma Cell Line

In vitro we transfect rAAV-anti2J2 into human tongue squamous cell carcinoma cell line Tca-8113 and then transplant it to the subcutaneous tissues of nude mice to simulate partially the process of growth of tumor cells. On the 7th, 12th, 17th, 22nd, 27th and 32nd day of inoculating subcutaneously, measure precisely maximal diameter (a) and minimum diameter (b) with a vernier caliper, calculate the volume of tumor V=πnab²/6, and shape the growth curve of tumor volume. The result is as following. After inoculating Tca-8113 to nude mice and a latent phase of 4-7 days, subcutaneous tumor nodes can be observed by naked eyes and then grow rapidly. The growth cure of transplantation tumor in each group appears S-shape with the peak of growth among 12-22 days. As time goes on, the volume of transplantation tumor in each group turns significantly different. With the delay growth of transfected rAAV-antiCYP2J2 group, the growth curve appears S-shape by a right shift and on the 32nd day of transfecting rAAV-anti2J2, the volume of tumor is two times larger than the basal state. So CYP epoxygenase can obviously promote the growth of tumor in vivo and, if CYP epoxygenase gene expression is inhibited, inhibit the growth of tumor as shown in FIG. 12.

(4) Influence of rAAV-anti2J2 Epoxygenase on Microvessel Density of Tumor Tissues

With animals sacrificed 32 days after inoculating, peel off the tumor to prepare the paraffin section and count to analyse the microvessel density (MVD). Microscopically microvessels are observed, distributing mainly in mesenchymal cells of tumor tissues and its peripheral areas but seldom inside the tumor tissues. Microvessels increase in the transfected rAAV-CYP2J2 and rAAV-CYPF87V groups and their density is greater (76.8±9.1 and 70.2±7.8) in high power field significantly differing from the control group (42.8±6.4) (P<0.01). Microvessels in transfected rAAV-anti2J2 group, compared with the control group and transfected rAAV-CYP2J2 group, decrease obviously (P<0.05 and P<0.01) as shown in FIG. 13.

(5) Influence of rAAV-anti2J2 Epoxygenase on the Migration and Invasion of Tumor Cells

We measure the migration of epithelial cells in the modified Boyden chamber by a conventional method. Coat the polycarbonate filter membrane of μm aperture at 4C for 24 h with collagen IV(10 μg/mL) and Matrigel(11 μg/filter). Wash the Tca-8113, A549, Ncl-H446 and HepG2 cell lines with DMEM culture solution to 2×10⁶/mL. Add 200 μL of DMEM containing 5% FBS to the low part of the Boyden chamber as a chemoattractant and cover with a polycarbonate filter membrane. Add 800 μl of cell supernatant to the upper part of the Boyden chamber, culture at 37° C. with 5% CO₂ for 5 h, detach the device and remove the membrane. Clean off cells, immobilize the membrane with carbinol and stain with hematoxylin. Obverse randomly five fields of vision per membrane under a 200× microscope and calculate the number of migrating cells. Through several repeat experiments, it is verified that the transfection of rAAV-antiCYP2J2, together with utilization of the CYP epoxygenase inhibitor 17-ODYA, can decrease the ability of migrating of cells, which is about 60% of basal state (P<0.01) as shown in FIG. 14A and B.

The result shows rAAV-anti2J2 virus and CYP epoxygenase inhibitor (17-ODYA) have the ability to inhibit the proliferation and migration of tumor and can be used for tumor treatment. With successful construction of recombinant adeno-associated virus expressing antisense human CYP2J2 gene (rAAV-anti2J2), its long-term high expression in organism blocks the transcription and translation of CYP2J2 gene from gene level, decreases the expression of CYP2J2, and shows stronger and more thorough function. The clinical utilization of recombinant adeno-associated virus expressing antisense human CYP2J2 gene (rAAV-anti2J2) and CYP epoxygenase inhibitor will play an important role in the treatment for the disease harmful to human health as tumor etc.

EMBODIMENT 5 Influence of rAAV-anti2J2 Epoxygenase on the Apoptosis of Tumor Cells

In a similar manner described above, transfect rAAV-GFP, rAAV-anti2J2, rAAV-F87V and rAAV-CYP2J2 respectively into 4 different tumor cell lines, a week later use TNF to induce the apoptosis of tumor cells and measure the apoptosis through different methods. By DNA ladder, acridine orange staining and flow cytometry analysis, it is found that: {circle around (1)} Both adding EETs directly and transfecting rAAV-CYP2J2 or rAAV-CYPF87V can decrease obviously the formation of DNA ladder, but either using epoxygenase inhibitor 17-ODYA or transfecting rAAV-anti2J2 can promote obviously the apoptosis of tumor cells induced by TNF-α. {circle around (2)} Stain cells with acridine orange or ethidium bromide and observe under a fluorescent microscope that in the groups of transfecting epoxygenase gene and interfering directly with EETs a small quantity of cells exfoliate, the cell density is high and the number of apoptotic cells is obviously less than the control group. But obvious exfoliation occurs in tumor cells with 17-ODYA used or rAAV-anti2J2 transfected, the cell density decreases obviously, most nuclear chromatins condense and break into particles, and apoptotic cells increase obviously. It shows preliminarily from morphology that EETs and epoxygenase gene can both resist the apoptosis of tumor cells induced by TNF-α. {circle around (3)} After PI staining and Annexin V-FITC/PI dobule staining respectively, analyze the total apoptosis rate and early apoptosis rate of cells by flow cytometry. The result shows that the total apoptotic rate of the cells pretreated with 3 kinds of EETs is 14.94%±3.5, 11.72%±4.2 and 12.89%±2.7 respectively, which is obviously lower than the control group (28.15%±4.7,P<0.01) and the vehicle group (27.86%±6.1,P<0.01) and significantly lower than the 17-ODYA group(52.65%±3.6), and the total apoptotic rate of tumor cells of transfected CYP2J2 and CYPF87V is 7.24%±4.2 and 7.79%±2.7 respectively, which is obviously lower than the control group (20.15%±3.5,P<0.01), the 17-ODYA group (33.51%±6.1, P<0.01) and the transfected rAAV-anti2J2 group (40.74%±3.5, P<0.01). {circle around (4)} The research on the antiapoptosis mechanism of epoxygenase and EETs shows that EETs and transfecting epoxygenase gene can both increase very significantly the phosphorylation of Akt, up-regulate the expression of antiapoptosis protein Bcl-2 and Bcl-xL and down-regulate the expression of apoptosis protein Bax. And using CYP epoxygenase inhibitor and transfecting rAVV-anti2J2 have a complete counterproductive effect. The results show both epoxygenase and EETs can not only promote obviously the growth of tumor, but also protect tumor cells through inhibiting the cell apoptosis induced by TNF-α. According to the conclusion, using CYP epoxygenase inhibitor or transfecting rAVV-anti2J2 can promote the apoptosis of tumor so as to treat tumor.

While particular embodiments of the invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications may be made without departing from the invention in its broader aspects, and therefore, the aim in the appended claims is to cover all such changes and modifications as fall within the true spirit and scope of the invention. 

1. A recombinant adeno-associated virus expressing antisense human CYP2J2 gene, comprising three plasmids: pXX₂: a packing plasmid carrying sequences encoding Rep and Cap protein of adeno-associated virus. A p5 promoter is inserted in upstream and downstream respectively, making the expression efficiency increase 15-fold and providing the essential Rep proteins for rAAV duplication; pXXUF₁: an eukaryotic expression vector containing a CMV promoter and having a strong expression efficiency in which the NotI site in multiple cloning sites can link different target genes. pXXUF₁ links inversely the CYP epoxygenase gene and contains inverted terminal repeats (ITRs) that are essential for the expression of rAAV-mediated transgenosis and responsible for the replication of virus, package of virus capsid and carrying target genes; pXX₆: a helper plasmid deleting the pathogenic gene sequences of adenovirus and preserving the E1A, E2A and VA1 RNA genes of adenovirus. The expressed proteins can help to stimulate the transcription and translation of rAAV gene, so the yield of rAAV can be ensured; and Cotransfect three plasmids above into 293 cell by the calcium phosphate precipitation technique and obtain high titre rAAV particles containing target genes in 293 cell.
 2. A preparation method of the recombinant adeno-associated virus expressing antisense human CYP2J2 gene, comprising steps of: 1) plasmid pXX₂ - - - carrying sequences encoding Rep and Cap protein that are essential for the package of adeno-associated virus and plasmid pXX₆ - - - carrying E1A, E2A and VA1 RNA genes of adenovirus that are essential for stimulating the replication and transcription of adeno-associated virus; 2) an eukaryotic expression vector pXXUF₁ containing the adeno-associated virus genome, in which the coding region of cap and rep protein is deleted and the antisense human CYP2J2 gene is inserted to constitute a recombinant plasmid pXXUF₁-anti2J2; 3) pXX₂, pXX₆ of step 1) and pXXUF₁-anti2J2 of step 2) are transfected into 293 cell by the calcium phosphate precipitation technique, which are then recovered and purified, and the virus titre is measured by dot blot hybridization; and 4) detecting the expression and biological activity of the recovered and purified virus-transfected tumor cells of step
 3. 3. The recombinant adeno-associated virus expressing antisense human CYP2J2 gene of claim 1, wherein the recombinant adeno-associated virus is prepared through manual splicing, modifying and processing the natural AAV by molecular biology methods, then packing and replicating by molecular biology methods, and purifying.
 4. A combination of medicines, comprising the recombinant adeno-associated virus expressing antisense human CYP2J2 gene and the vector or excipient accepted in pharmacy.
 5. The recombinant adeno-associated virus expressing antisense human CYP2J2 gene of claim 1, wherein it can inhibit selectively the expression of CYP2J2 gene in tumor tissues and suppress the synthesis of epoxyeicosatrienoic acids so as to treat malignant tumor.
 6. The recombinant adeno-associated virus expressing antisense human CYP2J2 gene according to claim 1 or 5, wherein the chosen selective inhibitor of CYP epoxygenase, antagonist of epoxyeicosatrienoic acids to which CYP epoxygenase metabolizes AA, and other similar chemicals are artificially synthesized to inhibit selectively the activity of CYP epoxygenases and block the function of epoxyeicosatrienoic acids, and can control the proliferation of tumor but show no toxic effects on normal cells.
 7. The recombinant adeno-associated virus expressing antisense human CYP2J2 gene according to claim 1, wherein it is conserved in China Center for Type Culture Collection(CCTCC), Wuhan University, China with deposition Date: 30.06.2004, deposition NO(CCTCC No):V200411 and systematic nomenclature: recombinant adeno-associated virus expressing antisense human cytochrome P4502J2 gene. 